Open Access
VIEWPOINT
SARS-CoV-2 induced myocarditis: Current knowledge about its molecular and pathophysiological mechanisms
DOMENICO MARIA CARRETTA1,§, MARINA DI DOMENICO2,§, ROBERTO LOVERO3, ROBERTO ARRIGONI4, ANGELIKA ELZBIETA WEGIERSKA5, MARIAROSARIA BOCCELLINO2,*, ANDREA BALLINI2,6,*, IOANNIS ALEXANDROS CHARITOS7,#, LUIGI SANTACROCE5,#
1 AOU Policlinico Consorziale di Bari-Ospedale Giovanni XXIII, Cardiology Unit, Policlinico University Hospital of Bari, Bari, 70124, Italy
2 Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, Naples, 80138, Italy
3 AOU Policlinico Consorziale di Bari-Ospedale Giovanni XXIII, Clinical Pathology Unit, Policlinico University Hospital of Bari, Bari, 70124, Italy
4 CNR Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies (IBIOM), Bari, 70125, Italy
5 Department Interdisciplinary of Medicine, University of Bari “Aldo Moro”, Bari, 70124, Italy
6 School of Medicine, University of Bari “Aldo Moro”, Bari, 70124, Italy
7 Department of Emergency and Urgency, National Poisoning Centre, Riuniti University Hospital of Foggia, Foggia, 71122, Italy
* Corresponding Authors: Andrea Ballini, ; Mariarosaria Boccellino,
§ Contributed equally as co-first authors
# These authors contributed equally to this work
BIOCELL 2022, 46(8), 1779-1788. https://doi.org/10.32604/biocell.2022.020009
Received 29 October 2021; Accepted 22 December 2021; Issue published 22 April 2022
Abstract
The existence of an inflammatory process in the heart muscle, related to a progressive worsening of myocardial
function, different etiopathogenetic mechanisms concur and often overlap, thus making the diagnosis and the therapeutic
approach complex. As the COVID-19 pandemic progresses, the effects of the disease on the organ systems and in
particular on the cardiovascular system are becoming more and more profound. Cardiac involvement is a well-known
event with a high percentage of findings in the heart’s magnetic field, even in asymptomatic areas. There are
numerous uncertainties regarding their evolution, in the long and short term, due not only to a difficult to determine
the varied clinical expression and the rarely performed intramyocardial biopsy which additionally presents diagnostic
problems but also in part to different clinical prognosis. Today, the new SARS-CoV-2 virus that uses the angiotensin
converting enzyme 2 (ACE2) which is present at high levels in myocardial cells as its entrance it can create even
severe heart injury. The pathophysiology in all of these cases can involve multiple immune and non-immune
mechanisms within organs and vessels and can be occur in the clinical phases. Possible mechanisms of direct and
indirect myocardial infarction in patients with COVID-19 include additional lesion and oxygen-rich and generalized
inflammation response with myocardial immune hyperactivity (myocarditis). Therefore, these can occur through the
excessive release of cytokines, the presence of thrombocytopenia, endocrine damage, heart failure, arrhythmias and
more. Patients can show average signs of myocardial damage, and some develop spontaneous cardiac complications,
such as heart failure, arrhythmias and, rarely, rare cardiogenic disorders. Pathophysiology in all of these may involve
multiple mechanisms within the cytokine cephalic membrane, endocrine damage and thrombogenicity. The diagnosis
of this myocardial injuri is mainly based on the myocardial enzyme troponin. This viewpoint paper explains today’s
knowledge on viral myocarditis, in particular that from SARS-CoV-2 infection, if there is a connection with other
possible biomolecular pathogenetic factors that can influence its natural course. In fact, it is for this reason that the
pathogenetic mechanisms are analyzed and described. At the same time, its possible interaction with other parameters
that are documented risk factors for cardiovascular disease was examined. Although these biomolecular findings were
mainly related to necrotic parts of the myocardium, it is important to recognize that myocardial damage early for a
better approach and prognosis.
Keywords
Cite This Article
CARRETTA, D. M., DOMENICO, M. D., LOVERO, R., ARRIGONI, R., WEGIERSKA, A. E. et al. (2022). SARS-CoV-2 induced myocarditis: Current knowledge about its molecular and pathophysiological mechanisms.
BIOCELL, 46(8), 1779–1788. https://doi.org/10.32604/biocell.2022.020009